An update on emerging immunological targets and their inhibitors in the treatment of psoriasis.

Psoriasis is a non-communicable, heterogeneous, autoimmune, inflammatory skin disease characterised by reddish, scaly plaques that grow over time. Psoriasis affects people in all countries with all age groups. The World Psoriasis Day organisation claims that out of 125 million people on this planet - Psoriasis affects about 2.5% to 3% of the population. The symptoms of psoriasis are unpredictable, and there are several external factors and associated comorbidities including psoriatic arthritis, renal failure, gastrointestinal disease, cardiovascular disease, stroke, obesity, diabetes, hypertension, mental disorders, cancer and a higher risk of death due to the systemic inflammation associated with the condition. In 2014, the WHA resolution identified that psoriasis is a severe non-communicable condition that affects both men and women. According to the declaration, several individuals suffer excessively from psoriasis all across the world as a result of inaccurate or delayed diagnosis, poor treatment solutions, minimal healthcare access, and social stigmatisation. Focusing on the function of cytokines and small-molecule inhibitors in the pathogenesis of disease could benefit the development of newer anti-psoriasis therapies. This is an updated comprehensive review that provides insight into the management of psoriasis with different therapeutic approaches and gives a brief idea about immunological signalling molecules that play a crucial part in the disease progression. We also highlighted the potential involvement of interleukins in the context of psoriasis, which may help the research community in its hunt for new treatments.